Centers | ||
Edinburgh Drug Discovery | Saint Louis University Institute for Drug and Biotherapeutic Innovation (IDBI) | VMCC, University of Michigan |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
The IDBI is a decentralized, collaborative institute whose mission is to promote the translation of research projects at Saint Louis University through drug discovery and pre-clinical development. The IDBI achieves this through four main... |
The VMCC is an on-campus core facility for the design and synthesis of drug-like molecules and diagnostic probes used in biomedical investigations. Our Mission: To assist biomedical researchers in translating novel therapeutic hypotheses into... |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all GSK and MD Anderson to co-develop new cancer therapeuticsGlaxoSmithkline and MD Anderson Cancer Center entered into a co-development and license agreement to develop antibody based therapeutics to treat cancer. Under this agreement MD Anderson grants exclusive rights to antibodies developed during the... View all UCB To Fund "Mining the Human Microbiome" Project at HarvardUCB as agreed to fund and support a third research project called "Mining the Human Microbiome" as part of the UCB-Harvard Research Alliance. UCB will be providing $4.5 million over a period of three years to immunologists at Harvard to study the... View all |
No EVENTS for listing |
No Job Posts |


